WO2022230494A1 - 免疫細胞の代謝促進用組成物 - Google Patents
免疫細胞の代謝促進用組成物 Download PDFInfo
- Publication number
- WO2022230494A1 WO2022230494A1 PCT/JP2022/014256 JP2022014256W WO2022230494A1 WO 2022230494 A1 WO2022230494 A1 WO 2022230494A1 JP 2022014256 W JP2022014256 W JP 2022014256W WO 2022230494 A1 WO2022230494 A1 WO 2022230494A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ergothioneine
- composition
- salt
- present
- metabolism
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 62
- 230000019522 cellular metabolic process Effects 0.000 title claims abstract description 18
- 230000004936 stimulating effect Effects 0.000 title abstract 4
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 120
- 150000003839 salts Chemical class 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000005934 immune activation Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 230000004060 metabolic process Effects 0.000 claims description 37
- 230000001737 promoting effect Effects 0.000 claims description 37
- 235000013305 food Nutrition 0.000 claims description 25
- 230000003213 activating effect Effects 0.000 claims description 22
- 230000004898 mitochondrial function Effects 0.000 claims description 21
- 230000003308 immunostimulating effect Effects 0.000 claims description 16
- 230000036039 immunity Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 description 28
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 28
- 230000000694 effects Effects 0.000 description 25
- 229940093497 ergothioneine Drugs 0.000 description 25
- 230000029058 respiratory gaseous exchange Effects 0.000 description 23
- 229940079593 drug Drugs 0.000 description 19
- 230000002407 ATP formation Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000036284 oxygen consumption Effects 0.000 description 11
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 10
- 230000002438 mitochondrial effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 102000002689 Toll-like receptor Human genes 0.000 description 5
- 108020000411 Toll-like receptor Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 4
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 4
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 4
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 4
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 4
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 4
- 240000001462 Pleurotus ostreatus Species 0.000 description 4
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 230000006677 mitochondrial metabolism Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 229930191479 oligomycin Natural products 0.000 description 4
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- -1 organic acid salts Chemical class 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 2
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 244000191482 Cantharellus cibarius Species 0.000 description 2
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 240000001080 Grifola frondosa Species 0.000 description 2
- 235000007710 Grifola frondosa Nutrition 0.000 description 2
- 240000000588 Hericium erinaceus Species 0.000 description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 240000002769 Morchella esculenta Species 0.000 description 2
- 235000002779 Morchella esculenta Nutrition 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 2
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004769 mitochondrial stress Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 2
- 229940080817 rotenone Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LJUIOEFZFQRWJG-GHYFRYPYSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-2-amino-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanylpropanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)CSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O LJUIOEFZFQRWJG-GHYFRYPYSA-N 0.000 description 1
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 235000008121 Agrocybe aegerita Nutrition 0.000 description 1
- 241000404030 Anacyclus clavatus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000222455 Boletus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000392443 Pleurotus citrinopileatus Species 0.000 description 1
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 1
- 241000222351 Pleurotus cornucopiae Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000006686 mitochondrial oxygen consumption Effects 0.000 description 1
- 230000006540 mitochondrial respiration Effects 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition for promoting metabolism of immune cells.
- the present invention also relates to compositions for immunostimulation.
- the present invention further relates to a method for promoting metabolism of immune cells, a method for activating immunity, and the like.
- immune cells also called immunocompetent cells
- leukocytes are generally classified into five types: monocytes (macrophages), lymphocytes, neutrophils, basophils, and eosinophils, which are immunocompetent cells involved in biological defense.
- monocytes macrophages
- lymphocytes lymphocytes
- neutrophils neutrophils
- basophils basophils
- eosinophils immunocompetent cells involved in biological defense.
- PBMC Peripheral blood mononuclear cells
- Ergothioneine is an amino acid contained in mushrooms and the like, and naturally exists in the L form.
- Patent Document 1 in mice to which ergothioneine was orally administered, peri-testicular fat weight was reduced compared to mice to which ergothioneine was not orally administered, and triglyceride (neutral fat) in plasma was reduced. It is stated that
- ergothioneine and any one of Toll-like receptor ligands selected from lipopolysaccharide (LPS), Pam2CSK4, synthetic triacylated lipoproteins and imidanoquinoline compounds are used as active ingredients to activate an immune response.
- Cytokine production-enhancing agents are disclosed, but in the absence of TLR ligands, IL-6, IL-12, IL-1 ⁇ and IL-10 were not detected in samples with both 0 and 10 mM ergothioneine. rice field.
- IL-6, IL-12, IL-1 ⁇ and IL-10 were not detected when TLRs were not stimulated, regardless of the presence or absence of ergothioneine (claim 1, etc., and paragraph [0068]). Therefore, immune response-activating cytokine production-enhancing agents containing ergothioneine and a specific Toll-like receptor ligand as active ingredients are known, but immune response-activating cytokine production-enhancing effects of ergothioneine alone are not known.
- US Pat. No. 6,200,303 discloses a method of protecting mitochondria from damage caused by irradiation, free radicals and reactive oxygen species, comprising administering a composition comprising L-ergothioneine to mitochondria parenterally, topically, transmucosally, transmucosally, or parenterally.
- Pulmonary or percutaneous administration is disclosed (claim 1, claim 8, etc.).
- the activation of mitochondrial function by L-ergothioneine is not disclosed at all, nor is there any description or suggestion of promotion of immune cell metabolism.
- JP 2011-102286 A Japanese Patent No. 6121597 Japanese Patent Publication No. 2001-513760
- L-ergothioneine or a salt thereof has the effect of promoting the metabolism of immune cells.
- An object of the present invention is to provide a composition for promoting metabolism of immune cells. Another object of the present invention is to provide an immunostimulatory composition. Another object of the present invention is to provide a method for promoting metabolism of immune cells and a method for activating immunity.
- L-ergothioneine has an effect of promoting the metabolism of immune cells.
- the present invention relates to the following compositions for promoting metabolism of immune cells, compositions for activating immunity, and the like.
- a composition for promoting metabolism of immune cells containing L-ergothioneine or a salt thereof as an active ingredient.
- the composition of [1] above which promotes metabolism of immune cells by activating mitochondrial function.
- An immunostimulatory composition comprising the composition of [1] or [2] above.
- [5] The composition according to any one of [1] to [4], which is a food or drink.
- composition according to any one of [1] to [5] above, wherein the content of L-ergothioneine or a salt thereof is 2 to 50 mg in terms of L-ergothioneine per day for adults.
- a method for promoting metabolism of immune cells comprising administering L-ergothioneine or a salt thereof.
- a method for activating immunity comprising administering L-ergothioneine or a salt thereof.
- Use of L-ergothioneine or a salt thereof for immune activation Use of L-ergothioneine or a salt thereof for immune activation.
- a composition for promoting metabolism of immune cells can be provided.
- FIG. 1A is a graph showing the effect of ergothioneine on oxygen consumption rate (OCR) on basal respiration
- FIG. 1B is a graph showing the effect of ergothioneine on OCR on ATP-related respiration
- FIG. 1C is a graph showing the OCR on maximal respiration of ergothioneine.
- is a graph showing the effect on Figure 2 is a graph showing the effect of ergothioneine on oxygen consumption rate (OCR) in human PBMC over time.
- composition for promoting metabolism of immune cells of the present invention contains L-ergothioneine or a salt thereof as an active ingredient.
- composition for promoting metabolism of immune cells of the present invention may be referred to as the composition of the first aspect of the present invention.
- L-ergothioneine is a kind of amino acid.
- the salt of L-ergothioneine is not particularly limited as long as it is a pharmacologically acceptable salt or a salt acceptable for food and drink, and may be either an acid salt or a basic salt.
- Acid salts include, for example, inorganic salts such as hydrochlorides, sulfates, nitrates, phosphates; Examples include organic acid salts such as acid salts and propionate salts.
- Examples of basic salts include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts;
- L-ergothioneine or a salt thereof may be a chemically synthesized product, or may be extracted and purified from natural products.
- a large amount of L-ergothioneine is contained in Golden/Yellow Oyster mushroom (scientific name: Pleurotus cornucopiae var. citrinopileatus), which is a mushroom belonging to the genus Oyster mushroom of the family Oysteraceae.
- L-ergothioneine is found in white button mushrooms, crimini mushrooms, portabella mushrooms and other mushrooms (scientific name: Agaricus bisporus), gray oyster mushrooms (scientific name: Pleurotus ostreatus), shiitake mushrooms (scientific name: Lentinula edodes), maitake mushrooms (Scientific name: Grifola Frondosa), Reishi (Scientific name: Ganoderma lucidum), Hericium erinaceus (Scientific name: Hericium erinaceus), Willow matsutake (Scientific name: Agrocybeaegerita), Chanterelle (Scientific name: Cantharellus cibarius), Porcini mushroom (Scientific name: Boletus) It is also contained in mushrooms such as Morchella esculenta (scientific name: Morchella esculenta).
- L-ergothioneine When L-ergothioneine is obtained from a natural product, it is preferably extracted from Pleurotus cornucopia. L-ergothioneine or a salt thereof can also be produced by microbial fermentation. An extract containing L-ergothioneine or a salt thereof produced by microbial fermentation, or a product purified therefrom may also be used. Extraction and purification from natural products and the like can be carried out by known methods. L-ergothioneine or a salt thereof may be isolated.
- L-ergothioneine or a salt thereof is a compound that is contained in natural products and foods and drinks and has been eaten. Therefore, from the viewpoint of safety, long-term intake of L-ergothioneine or a salt thereof is considered to pose few problems.
- L-ergothioneine increased the oxygen consumption rate (OCR) of peripheral blood mononuclear cells (PBMC) and also improved mitochondrial metabolism compared to the absence of L-ergothioneine. significantly increased.
- Mitochondria are intracellular organelles present in all organisms that utilize oxygen to produce energy in the form of adenosine triphosphate (ATP) and reduce it to water.
- Increased mitochondrial metabolism in peripheral blood mononuclear cells (PBMC) is indicated by increased mitochondrial basal respiration, maximal respiration, increased mitochondrial ATP production, and the like.
- OCR oxygen consumption rate
- compositions of the present invention preferably promote immune cell metabolism by activating mitochondrial function in immune cells.
- the use of L-ergothioneine significantly increased basal mitochondrial respiration, ATP production, and maximal respiration in peripheral blood mononuclear cells (PBMCs) compared to the absence of L-ergothioneine, and increased mitochondrial metabolism. A significant increase, thus activating mitochondrial function.
- the compositions of the invention can be used to promote immune cell metabolism by activating mitochondrial function.
- immune cells are preferably at least one selected from T cells, B cells, natural killer cells and monocytes.
- Peripheral blood mononuclear cells PBMCs
- T cells peripheral blood mononuclear cells
- B cells natural killer cells
- monocytes a cell that stimulates T cells, B cells, natural killer cells and monocytes. This is because it consists of The composition of the present invention promotes metabolism of at least one immune cell selected from T cells, B cells, natural killer cells and monocytes by activating mitochondrial function in peripheral blood mononuclear cells (PBMC). is preferred.
- L-ergothioneine or a salt thereof has an immunostimulatory effect because it has an effect of promoting the metabolism of immune cells and an effect of activating mitochondrial function in immune cells.
- L-ergothioneine or a salt thereof can be used as an active ingredient for immune activation.
- the composition for promoting immune cell metabolism can be used, for example, for immune activation. Therefore, the composition of the first aspect of the present invention can be used as an immunostimulatory composition.
- a composition for immunostimulation containing the composition of the first aspect of the present invention is also one aspect of the present invention.
- the composition for immunostimulation is also referred to as the composition of the second aspect of the present invention.
- composition of the first aspect and the composition of the second aspect of the present invention have an immunostimulatory effect and can be used to prevent or improve conditions or diseases caused by weakened immune function.
- Prevention of a condition or disease includes preventing onset, delaying onset, reducing the rate of onset, reducing the risk of onset, and the like.
- Ameliorating a condition or disease includes ameliorating the subject from the condition or disease, alleviating symptoms of the condition or disease, ameliorating symptoms of the condition or disease, slowing progression of the condition or disease, preventing the condition or disease. etc.
- Conditions or diseases caused by a weakened immune system include infectious diseases caused by microorganisms such as viruses and bacteria; Influenza due to infection, cold syndrome, stomatitis due to oral infection, periodontal disease, etc., various malignant tumors, for example, epithelial malignant tumors that occur in solid organs such as the gastrointestinal tract, respiratory mucosa, liver and kidneys, Examples include non-epithelial malignant tumors occurring in locomotive organs and soft tissues.
- infectious diseases also include, for example, symptoms derived from viruses that have been infected in the past and are dormant inside the subject, such as herpes virus.
- the composition of the present invention is preferably used for preventing or ameliorating at least one selected from the above symptoms or diseases.
- composition for promoting metabolism of immune cells and the composition for activating immunity of the present invention may be collectively referred to simply as the composition of the present invention.
- compositions of the present invention can be applied for either therapeutic use (medical use) or non-therapeutic use (non-medical use).
- Non-therapeutic is a concept that does not involve medical intervention, i.e. human surgery, treatment or diagnosis.
- the composition of the present invention can be provided in the form of a drug, but is not limited to this form.
- the agent itself can be provided as a composition, or a composition containing the agent can be provided.
- the composition for promoting immune cell metabolism of the present invention can also be referred to as an immune cell metabolism promoting agent.
- the composition for immunostimulation of the present invention can also be called an immunostimulator.
- the composition of the present invention is preferably an oral composition.
- Oral compositions include food and drink, oral pharmaceuticals, quasi-drugs, and feeds, preferably food and drink or oral pharmaceuticals, and more preferably food and drink.
- composition of the present invention can contain optional additives and components in addition to L-ergothioneine or its salt as long as the effects of the present invention are not impaired.
- additives and components can be selected according to the form of the composition, etc., and those generally usable for foods and drinks, pharmaceuticals, quasi-drugs, feeds, etc. can be used.
- the compositions of the present invention do not contain Toll-like receptor ligands.
- the manufacturing method is not particularly limited, and it can be manufactured by a general method.
- composition of the present invention when used as a food or drink, L-ergothioneine or a salt thereof is blended with ingredients that can be used for food or drink (for example, food materials, food additives used as necessary).
- the food and drink are not particularly limited, and examples thereof include general food and drink, health food, health drink, food with function claims, food for specified health use, health supplement, and food and drink for the sick.
- Health foods, foods with function claims, foods for specified health uses, health supplements, etc. are various formulations such as fine granules, tablets, granules, powders, capsules, chewable formulations, syrups, liquid formulations, and liquid diets. can be in the form
- composition of the present invention is used as a drug or quasi-drug, for example, L-ergothioneine or a salt thereof is blended with a pharmacologically acceptable carrier, an additive added as necessary, and the like, It can be used as pharmaceuticals or quasi-drugs in various dosage forms.
- Such carriers, additives, etc. may be those that can be used for pharmaceuticals or quasi-drugs and are pharmacologically acceptable.
- antioxidants, coloring agents and the like can be mentioned.
- the dosage form of the drug or quasi-drug includes oral or parenteral dosage form, and oral dosage form is preferable from the viewpoint of obtaining the effect of the present invention more sufficiently.
- composition of the present invention When used as a drug or quasi-drug, it is preferably an oral drug or quasi-drug.
- Dosage forms for oral administration include liquids, tablets, powders, fine granules, granules, dragees, capsules, suspensions, emulsions, chewables and the like.
- Dosage forms for parenteral administration include injections and infusions.
- Pharmaceuticals and quasi-drugs may be for non-human animals.
- feed When the composition of the present invention is used as a feed, L-ergothioneine or a salt thereof may be added to the feed.
- Feed also includes feed additives. Examples of feeds include livestock feeds for cows, pigs, chickens, sheep, horses, etc.; small animal feeds for rabbits, rats, mice, etc.; pet foods for dogs, cats, small birds, etc.;
- the content of L-ergothioneine or a salt thereof contained in the composition of the present invention is not particularly limited, and can be set according to its form and the like.
- the content of L-ergothioneine or a salt thereof in the composition of the present invention is, for example, preferably 0.0001% by weight or more, more preferably 0.001% by weight or more, and 90% by weight or less in terms of L-ergothioneine. is preferred, and 50% by weight or less is more preferred.
- the content of L-ergothioneine or a salt thereof in the composition is preferably 0.0001 to 90% by weight, more preferably 0.001 to 50% by weight in terms of L-ergothioneine.
- the content of L-ergothioneine or a salt thereof is preferably within the above range.
- the amount in terms of L-ergothioneine or a similar expression is obtained by multiplying the amount in the case of L-ergothioneine or the number of moles of the salt in the case of a salt of L-ergothioneine by the molecular weight of L-ergothioneine. value.
- the composition of the present invention can be ingested or administered by an appropriate method depending on its form. From the viewpoint of obtaining the effect of the present invention more sufficiently, the composition of the present invention is preferably taken orally (orally administered).
- the intake amount (can also be referred to as dosage) of the composition of the present invention is not particularly limited as long as it is an amount that can obtain the effect of promoting the metabolism of immune cells, and the amount that can obtain the effect of activating immune function. It may be set as appropriate according to the dosage form, administration method, body weight of the subject, and the like.
- the intake of L-ergothioneine or a salt thereof is preferably 2 mg or more in terms of L-ergothioneine per day. , more preferably 5 mg or more, still more preferably 10 mg or more, more preferably 50 mg or less, more preferably 25 mg or less, still more preferably 20 mg or less.
- the intake of L-ergothioneine or a salt thereof is preferably 2 to 50 mg, more preferably 5 mg per day in terms of L-ergothioneine.
- the composition of the present invention may be an oral composition for ingesting or administering L-ergothioneine or a salt thereof in the above amount per 60 kg body weight per day to humans.
- the dose of L-ergothioneine or a salt thereof is preferably 2 to 50 mg, for example, preferably 2 to 50 mg per day, in terms of L-ergothioneine.
- It is preferably 5 to 25 mg, more preferably 5 to 20 mg, particularly preferably 10 to 20 mg.
- the composition of the present invention preferably has a content of L-ergothioneine or a salt thereof of 2 to 50 mg in terms of L-ergothioneine per day for adults.
- the content of L-ergothioneine or a salt thereof is more preferably 5 to 25 mg, more preferably 5 to 20 mg, and particularly preferably 10 mg per day for adults in terms of L-ergothioneine. ⁇ 20 mg.
- compositions of the present invention are taken or administered continuously.
- the composition of the present invention is preferably taken or administered continuously for one week or more, more preferably two weeks or more.
- Subjects to whom the composition of the present invention is ingested or administered are not particularly limited.
- the subject is preferably a human or non-human mammal, more preferably a human.
- Subjects to which the composition of the present invention is to be ingested or administered include those who require or desire immune cell metabolism promotion and those who require or desire immune activation.
- the subject of administration includes a subject with a condition or disease caused by a weakened immune system.
- the subject of administration of the composition of the present invention may be a healthy subject.
- the subject of administration of the composition of the present invention may be a healthy person whose immune function by immune cells is declining with age.
- the composition of the present invention may be labeled with a function exerted by promoting the metabolism of immune cells or a function exerted by activating the immune function.
- the composition of the present invention may be labeled with one or more functions such as "metabolism promotion of immune cells", “activation of mitochondrial function", “immune activation” and the like.
- the composition of the present invention is preferably a food or drink labeled as above.
- the above display may be a display to the effect that it is used to obtain the above functions.
- the label may be attached to the composition itself, or may be attached to the container or package of the composition.
- the invention also includes the following methods and uses.
- a method for promoting metabolism of immune cells comprising ingesting or administering L-ergothioneine or a salt thereof.
- a method for promoting metabolism of immune cells by activating mitochondrial function comprising ingesting or administering L-ergothioneine or a salt thereof.
- a method for activating immunity comprising ingesting or administering L-ergothioneine or a salt thereof.
- Use of L-ergothioneine or a salt thereof for promoting metabolism of immune cells Use of L-ergothioneine or a salt thereof for promoting immune cell metabolism by activating mitochondrial function.
- the metabolism of immune cells can be promoted, and the activation effect of mitochondrial function can promote the metabolism of immune cells, resulting in an immunostimulatory effect. can be obtained.
- the method of promoting immune cell metabolism can be used, for example, for immune activation.
- L-ergothioneine or a salt thereof is taken or administered orally.
- the method may be a therapeutic method or a non-therapeutic method.
- the use may be therapeutic use or non-therapeutic use.
- L-ergothioneine or salts thereof, preferred embodiments thereof, etc. are the same as those of the composition of the present invention described above.
- the subject take or administer L-ergothioneine or a salt thereof once or more times a day, for example, once to several times (eg, 2 to 3 times) a day.
- the above uses are preferably in humans or non-human mammals, more preferably in humans.
- L-ergothioneine or a salt thereof can be used to obtain an immunostimulatory effect by promoting immune cell metabolism and by promoting immune cell metabolism by activating mitochondrial function.
- an amount of L-ergothioneine or a salt thereof that provides an effect of promoting the metabolism of immune cells may be used.
- L-ergothioneine or a salt thereof may be used in an amount that provides an activating effect on mitochondrial function (can also be called an effective amount).
- an amount of L-ergothioneine or a salt thereof that provides an immunostimulatory effect may be used.
- the preferred dose, administration subject, etc. of L-ergothioneine or a salt thereof are the same as those of the composition of the present invention described above.
- L-ergothioneine or a salt thereof may be ingested or administered as is, or may be ingested or administered as a composition containing it.
- a composition of the invention may be ingested or administered.
- L-ergothioneine or a salt thereof can be used for the production of foods and drinks, pharmaceuticals, quasi-drugs, feeds, etc., which are used to promote the metabolism of immune cells.
- the present invention also includes the use of L-ergothioneine or a salt thereof for producing a composition for promoting metabolism of immune cells.
- the present invention also includes L-ergothioneine or a salt thereof, which is used for promoting metabolism of immune cells.
- L-ergothioneine or a salt thereof can be used for the production of foods and drinks, pharmaceuticals, quasi-drugs, feeds, etc. used for mitochondrial function activation.
- the present invention also includes the use of L-ergothioneine or a salt thereof for manufacturing a composition for activating mitochondrial function.
- the present invention also includes L-ergothioneine or a salt thereof used for mitochondrial function activation.
- L-ergothioneine or a salt thereof can be used for the production of foods and drinks, pharmaceuticals, quasi-drugs, feeds, etc. used for immune activation.
- the present invention also includes the use of L-ergothioneine or a salt thereof for manufacturing an immunostimulatory composition.
- the present invention also includes L-ergothioneine or a salt thereof used for immune activation.
- Example 1 The effect of the compound of the invention (L-ergothioneine) on mitochondrial function was analyzed.
- Ergothioneine was added to human peripheral blood mononuclear cells (PBMC) under the following conditions, and extracellular oxygen levels and pH were measured in real time using an XFe96 flux analyzer (manufactured by Agilent Technologies).
- XFe96 flux analyzer manufactured by Agilent Technologies.
- XFe technology uses solid-state sensors to simultaneously measure both oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) to simultaneously determine effects on oxidative phosphorylation (OXPHOS) and glycolysis. It is.
- OXPHOS oxidative phosphorylation
- FIG. Cells were then sequentially exposed to different inhibitors of mitochondrial function to assess cellular metabolism.
- Human PBMC were maintained in XF assay medium (XF RPMI1640 medium). At that time, L-ergothioneine was adjusted to final concentrations of 0, 10, 30 and 100 ⁇ M. 30,000 cells/50 ⁇ L/well of cells were seeded on a PDL-coated XF96-well cell culture plate and centrifuged at 200 g for 1 minute to adhere the cells. After 20 minutes of incubation at 37°C in the absence of CO2 , 130 ⁇ L of XF assay medium was gently added and incubated for an additional 40 minutes at 37°C in the absence of CO2 . The human PBMC to which ergothioneine was added was subjected to the following mitochondrial stress test.
- ⁇ Mitochondrial stress test> The XF Mitostress Kit (manufactured by Agilent Technologies) was used for the experiment. The following compounds (1) to (3) were sequentially added to the human PBMCs to which ergothioneine was added, and OCR was measured to determine basal respiration, ATP production, maximum Parameters such as respiration were calculated. The results obtained are shown in FIG. 1A (basal respiration), FIG. 1B (ATP production) and FIG. 1C (maximal respiration). This can aid in understanding the possible mechanisms of mitochondrial metabolism.
- Compound (1) 1 ⁇ M oligomycin, (2) 1 ⁇ M FCCP (carbonyl cyanide-p-trifluoromethoxyphenylhydrazone), and (3) 0.5 ⁇ M rotenone and antimycin A
- FCCP carbonyl cyanide-p-trifluoromethoxyphenylhydrazone
- Oligomycin is a known inhibitor of ATP synthase and prevents the production of ATP. Oligomycin treatment provides a measure of oxygen consumption associated with ATP production and ATP turnover. Addition of oligomycin results in decreased OCR under normal conditions, and residual OCR is associated with spontaneous proton leakage.
- FCCP is a protonophore and a known oxygen-consuming uncoupler from ATP production. FCCP processing allows the highest achievable electron transfer and oxygen consumption rates and provides a measure of reserve capacity.
- Rotenone and antimycin A are known inhibitors of complexes I and III of the electron transport chain, respectively. Upon treatment with these components, electron transfer is completely inhibited and residual oxygen consumption is due to non-mitochondrial activity by oxygen-requiring enzymes.
- FIG. 1A is a graph showing the effect of ergothioneine on OCR on basal respiration, and it can be confirmed that mitochondrial basal respiration is significantly increased in human PBMCs to which ergothioneine was added at final concentrations of 10 ⁇ M, 30 ⁇ M, and 100 ⁇ M. .
- FIG. 1B is a graph showing the effect of ergothioneine on OCR on ATP-related respiration, confirming that mitochondrial ATP production is significantly increased in human PBMCs to which ergothioneine was added at final concentrations of 10 ⁇ M, 30 ⁇ M, and 100 ⁇ M. can.
- FIG. 1C is a graph showing the effect of ergothioneine on OCR on maximal respiration, and it can be confirmed that maximal respiration of mitochondria is significantly increased in human PBMCs to which ergothioneine was added at final concentrations of 10 ⁇ M, 30 ⁇ M, and 100 ⁇ M. .
- FIG. 2 is a graph showing the effect of ergothioneine on oxygen consumption rate (OCR) in human PBMC over time. Ergothioneine added at final concentrations of 10 ⁇ M, 30 ⁇ M, and 100 ⁇ M increased mitochondrial oxygen consumption rate in human PBMC. It can be confirmed that
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
加齢に伴ってこれらの免疫細胞による免疫機能が低下することが知られており、主な原因として、T細胞の生産を担当する胸腺と、リンパ球を多く含んだ脾臓の萎縮が加齢とともに他の臓器に比べて、速くなることが考えられている。
〔1〕L-エルゴチオネイン又はその塩を有効成分として含有する、免疫細胞の代謝促進用組成物。
〔2〕ミトコンドリア機能の活性化により免疫細胞の代謝を促進する上記〔1〕に記載の組成物。
〔3〕上記〔1〕又は〔2〕に記載の組成物を含む免疫活性化用組成物。
〔4〕経口用組成物である上記〔1〕~〔3〕のいずれかに記載の組成物。
〔5〕飲食品である上記〔1〕~〔4〕のいずれかに記載の組成物。
〔6〕L-エルゴチオネイン又はその塩の含有量が、成人の1日摂取量当たり、L-エルゴチオネイン換算で2~50mgである上記〔1〕~〔5〕のいずれかに記載の組成物。
〔7〕L-エルゴチオネイン又はその塩を投与する、免疫細胞の代謝促進方法。
〔8〕L-エルゴチオネイン又はその塩を投与する、免疫活性化方法。
〔9〕免疫細胞の代謝促進のための、L-エルゴチオネイン又はその塩の使用。
〔10〕免疫活性化のための、L-エルゴチオネイン又はその塩の使用。
L-エルゴチオネインの塩としては、薬理学的に許容される塩又は飲食品に許容される塩であれば特に限定されず、酸性塩及び塩基性塩のいずれであってもよい。酸性塩として、例えば、塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩;酢酸塩、クエン酸塩、マレイン酸塩、リンゴ酸塩、シュウ酸塩、乳酸塩、コハク酸塩、フマル酸塩、プロピオン酸塩等の有機酸塩等が挙げられる。塩基性塩として、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩;カルシウム塩、マグネシウム塩等のアルカリ土類金属塩等が挙げられる。
ミトコンドリアは、エネルギーをアデノシン三リン酸(ATP)の形で生成し、還元して水となるような酸素を利用する有機体全てに存在する細胞内小器官である。末梢血単核細胞(PBMC)のミトコンドリアの代謝の増加は、ミトコンドリアの基礎呼吸、最大呼吸の増加、ミトコンドリアのATP産生量の増加等により示される。ミトコンドリアの基礎呼吸、最大呼吸の増加及びATP産生量の増加は、すなわち、ミトコンドリア機能の活性化によるエネルギー産生の増加であり、これらを免疫細胞の代謝促進の指標とすることができる。
よって、L-エルゴチオネインは、免疫細胞の代謝促進のための有効成分として使用することができる。なお、細胞の酸素消費速度(OCR)、ミトコンドリアの基礎呼吸、最大呼吸及びATP産生量は、公知の方法で測定することができ、例えば、後記の実施例に示すように、XFe96フラックスアナライザー(Agilent Technologies社製)を用いて測定することができる。
よって、本発明の第一の態様の組成物は、免疫活性化用組成物に使用することができる。本発明の第一の態様の組成物を含む免疫活性化用組成物も、本発明の一つである。
以下、免疫活性化用組成物を本発明の第二の態様の組成物もという。
状態又は疾患の予防は、発症を防止すること、発症を遅延させること、発症率を低下させること、発症のリスクを軽減すること等を包含する。状態又は疾患の改善は、対象を状態又は疾患から回復させること、状態又は疾患の症状を軽減すること、状態又は疾患の症状を好転させること、状態又は疾患の進行を遅延させること、防止すること等を包含する。
本発明の組成物は、上記の症状又は疾患から選択される少なくとも1種を予防又は改善するために使用されることが好ましい。
本発明の組成物は、一例として、剤の形態で提供することができるが、本形態に限定されるものではない。当該剤をそのまま組成物として、又は、当該剤を含む組成物として提供することもできる。一態様において、本発明の免疫細胞の代謝促進用組成物は、免疫細胞の代謝促進剤ということもできる。また、一態様において本発明の免疫活性化用組成物は、免疫活性化剤ということもできる。
本発明の効果を充分に得る観点から、本発明の組成物は、好ましくは経口用組成物である。経口用組成物としては、飲食品、経口用の医薬品、医薬部外品、飼料が挙げられ、好ましくは飲食品又は経口用医薬品であり、より好ましくは飲食品である。
本発明の組成物中のL-エルゴチオネイン又はその塩の含有量は、例えば、L-エルゴチオネイン換算で0.0001重量%以上が好ましく、0.001重量%以上がより好ましく、また、90重量%以下が好ましく、50重量%以下がより好ましい。一態様において、L-エルゴチオネイン又はその塩の含有量は、組成物中にL-エルゴチオネイン換算で0.0001~90重量%が好ましく、0.001~50重量%がより好ましい。一態様において、本発明の組成物を飲食品、医薬品、医薬部外品、飼料等とする場合、L-エルゴチオネイン又はその塩の含有量を上記範囲とすることが好ましい。
L-エルゴチオネイン換算の量、又はこれに類する表現は、L-エルゴチオネインの場合は、その量を、L-エルゴチオネインの塩の場合は、当該塩のモル数に、L-エルゴチオネインの分子量を乗じて得られる値を意味する。
一態様において、本発明の組成物を、ヒト(成人)に非経口投与する場合、L-エルゴチオネイン又はその塩の投与量は、1日当たり、L-エルゴチオネイン換算で、例えば好ましくは2~50mg、より好ましくは5~25mg、さらに好ましくは5~20mg、特に好ましくは10~20mgである。
一態様においては、ヒト(成人)の場合、1日当たり体重60kg当たり上記量のL-エルゴチオネイン又はその塩を摂取させる又は投与することが好ましい。
従って好ましい態様において、本発明の組成物は、継続して摂取又は投与されるものである。本発明の一実施態様において、本発明の組成物は、好ましくは1週間以上、より好ましくは2週間以上継続して摂取又は投与されることが好ましい。
本発明の組成物を摂取させる又は投与する対象として、免疫細胞の代謝促進を必要とする又は希望する対象、免疫活性化を必要とする又は希望する対象が挙げられる。一態様において、投与対象として、免疫機能の低下によって引き起こされる状態又は疾患を有する対象が挙げられる。一態様において、本発明の組成物の投与対象は、健常者であってよい。また、本発明の組成物の投与対象は、加齢に伴って免疫細胞による免疫機能が低下している健常者であってもよい。
本発明の一態様において、本発明の組成物は、上記の表示が付された飲食品であることが好ましい。また上記の表示は、上記の機能を得るために用いる旨の表示であってもよい。上記表示は、組成物自体に付されてもよいし、組成物の容器又は包装に付されていてもよい。
L-エルゴチオネイン又はその塩を摂取させる又は投与する、免疫細胞の代謝促進方法。
L-エルゴチオネイン又はその塩を摂取させる又は投与する、ミトコンドリア機能の活性化による免疫細胞の代謝促進方法。
L-エルゴチオネイン又はその塩を摂取させる又は投与する、免疫活性化方法。
免疫細胞の代謝促進のための、L-エルゴチオネイン又はその塩の使用。
ミトコンドリア機能の活性化による免疫細胞の代謝促進のための、L-エルゴチオネイン又はその塩の使用。
免疫活性化のための、L-エルゴチオネイン又はその塩の使用。
L-エルゴチオネイン又はその塩を対象に摂取させる又は投与すると、免疫細胞の代謝を促進することができ、また、ミトコンドリア機能の活性化効果により免疫細胞の代謝を促進することができ、免疫活性化効果を得ることができる。一態様において、免疫細胞の代謝促進方法は、例えば、免疫活性化のために使用することができる。好ましくは、L-エルゴチオネイン又はその塩を経口で摂取させる又は投与する。
上記方法は、治療的な方法であってもよく、非治療的な方法であってもよい。上記使用は、治療的な使用であってもよく、非治療的な使用であってもよい。
また、上記方法及び使用においては、ミトコンドリア機能の活性化効果が得られる量(有効量ということもできる)のL-エルゴチオネイン又はその塩を使用すればよい。
また、上記方法及び使用においては、免疫活性化効果が得られる量(有効量ということもできる)のL-エルゴチオネイン又はその塩を使用すればよい。
L-エルゴチオネイン又はその塩の好ましい投与量や投与対象等は上述した本発明の組成物と同じである。L-エルゴチオネイン又はその塩は、そのまま摂取又は投与してもよく、これを含む組成物として摂取又は投与してもよい。例えば、本発明の組成物を摂取又は投与してもよい。
本発明は、免疫細胞の代謝促進のために使用される、L-エルゴチオネイン又はその塩も包含する。
また、L-エルゴチオネイン又はその塩は、ミトコンドリア機能活性化のために使用される飲食品、医薬品、医薬部外品、飼料等の製造のために使用することができる。一態様において、本発明は、ミトコンドリア機能活性化用組成物を製造するための、L-エルゴチオネイン又はその塩の使用も包含する。
本発明は、ミトコンドリア機能活性化のために使用される、L-エルゴチオネイン又はその塩も包含する。
また、L-エルゴチオネイン又はその塩は、免疫活性化のために使用される飲食品、医薬品、医薬部外品、飼料等の製造のために使用することができる。一態様において、本発明は、免疫活性化用組成物を製造するための、L-エルゴチオネイン又はその塩の使用も包含する。
本発明は、免疫活性化のために使用される、L-エルゴチオネイン又はその塩も包含する。
ミトコンドリア機能に対する本発明の化合物(L-エルゴチオネイン)の効果を分析した。ヒト末梢血単核細胞(PBMC)にエルゴチオネインを下記条件で添加し、リアルタイムで、XFe96フラックスアナライザー(Agilent Technologies社製)を使用して細胞外酸素レベルおよびpHを測定した。XFe技術は、固体状態センサーを使用して、酸素消費速度(OCR)と細胞外酸性化率(ECAR)の両方を同時に測定して、酸化的リン酸化(OXPHOS)と解糖に対する効果を同時に求めるものである。得られた酸素消費速度(OCR)に関する結果を図2に示す。次いで、細胞をミトコンドリア機能の種々の阻害剤に順次曝露して、細胞代謝を評価した。
ヒトPBMCはXFアッセイ培地(XF RPMI1640培地)中に保持した。その際、L-エルゴチオネインが終濃度0、10、30、100μMになるように調製した。30,000個/50μL/ウェルの細胞をPDLコートしたXF96ウェル細胞培養プレートに播種し、200g、1分間遠心分離にて細胞を接着させた。37℃、CO2非存在下で20分培養後、130μLのXFアッセイ培地を静かに添加し、さらに40分間37℃、CO2非存在下で培養した。得られたエルゴチオネインが添加されたヒトPBMCについて、下記のミトコンドリアストレス試験を行った。
実験にはXF ミトストレスキット(Agilent Technologies社製)を用いた。得られたエルゴチオネインが添加されたヒトPBMCに下記(1)~(3)の化合物を順次細胞に加え、OCRを測定することにより、ミトコンドリア機能評価における主要な指標である基礎呼吸、ATP産生、最大呼吸などのパラメーターを算出した。得られた結果を、図1A(基礎呼吸)、図1B(ATP産生)及び図1C(最大呼吸)に示す。これにより、ミトコンドリア代謝の考えられる機序の理解を助けることができる。
化合物:
(1)1μM オリゴマイシン、
(2)1μM FCCP(カルボニルシアニド-p-トリフルオロメトキシフェニルヒドラゾン)、および
(3)0.5μM ロテノンおよびアンチマイシンA
(1)~(3)の化合物を順に加えてOCRを測定することにより、順にミトコンドリアの基礎呼吸、ATP産生、最大呼吸を評価できる。
Claims (10)
- L-エルゴチオネイン又はその塩を有効成分として含有する、免疫細胞の代謝促進用組成物。
- ミトコンドリア機能の活性化により免疫細胞の代謝を促進する請求項1に記載の組成物。
- 請求項1又は2に記載の組成物を含む免疫活性化用組成物。
- 経口用組成物である請求項1~3のいずれか一項に記載の組成物。
- 飲食品である請求項1~4のいずれか一項に記載の組成物。
- L-エルゴチオネイン又はその塩の含有量が、成人の1日摂取量当たり、L-エルゴチオネイン換算で2~50mgである請求項1~5のいずれか一項に記載の組成物。
- L-エルゴチオネイン又はその塩を投与する、免疫細胞の代謝促進方法。
- L-エルゴチオネイン又はその塩を投与する、免疫活性化方法。
- 免疫細胞の代謝促進のための、L-エルゴチオネイン又はその塩の使用。
- 免疫活性化のための、L-エルゴチオネイン又はその塩の使用。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280030903.7A CN117255683A (zh) | 2021-04-26 | 2022-03-25 | 免疫细胞的代谢促进用组合物 |
EP22795412.0A EP4331582A1 (en) | 2021-04-26 | 2022-03-25 | Composition for stimulating immune cell metabolism |
JP2023517172A JPWO2022230494A1 (ja) | 2021-04-26 | 2022-03-25 | |
AU2022265114A AU2022265114A1 (en) | 2021-04-26 | 2022-03-25 | Composition for stimulating immune cell metabolism |
US18/286,634 US20240122899A1 (en) | 2021-04-26 | 2022-03-25 | Composition for stimulating immune cell metabolism |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021074323 | 2021-04-26 | ||
JP2021-074323 | 2021-04-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022230494A1 true WO2022230494A1 (ja) | 2022-11-03 |
Family
ID=83847368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/014256 WO2022230494A1 (ja) | 2021-04-26 | 2022-03-25 | 免疫細胞の代謝促進用組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240122899A1 (ja) |
EP (1) | EP4331582A1 (ja) |
JP (1) | JPWO2022230494A1 (ja) |
CN (1) | CN117255683A (ja) |
AU (1) | AU2022265114A1 (ja) |
TW (1) | TW202308615A (ja) |
WO (1) | WO2022230494A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513760A (ja) | 1997-02-20 | 2001-09-04 | オクシス インターナショナル インコーポレイテッド | ミトコンドリアの保護方法及びそのための組成物 |
JP2011102286A (ja) | 2009-04-27 | 2011-05-26 | Iwade Kingaku Kenkyusho:Kk | 脂肪減少等の活性を示す組成物 |
JP2012180329A (ja) * | 2011-03-02 | 2012-09-20 | Hokkaido Univ | 抗微生物物質産生・分泌促進剤 |
WO2014004647A1 (en) * | 2012-06-26 | 2014-01-03 | Entia Biosciences, Inc. | A nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2 |
JP6121597B1 (ja) | 2016-06-09 | 2017-04-26 | 株式会社スリービー | 免疫応答活性化サイトカイン産生促進剤およびTh17細胞分化促進剤 |
-
2022
- 2022-03-25 JP JP2023517172A patent/JPWO2022230494A1/ja active Pending
- 2022-03-25 WO PCT/JP2022/014256 patent/WO2022230494A1/ja active Application Filing
- 2022-03-25 AU AU2022265114A patent/AU2022265114A1/en active Pending
- 2022-03-25 CN CN202280030903.7A patent/CN117255683A/zh active Pending
- 2022-03-25 US US18/286,634 patent/US20240122899A1/en active Pending
- 2022-03-25 EP EP22795412.0A patent/EP4331582A1/en active Pending
- 2022-04-21 TW TW111115152A patent/TW202308615A/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513760A (ja) | 1997-02-20 | 2001-09-04 | オクシス インターナショナル インコーポレイテッド | ミトコンドリアの保護方法及びそのための組成物 |
JP2011102286A (ja) | 2009-04-27 | 2011-05-26 | Iwade Kingaku Kenkyusho:Kk | 脂肪減少等の活性を示す組成物 |
JP2012180329A (ja) * | 2011-03-02 | 2012-09-20 | Hokkaido Univ | 抗微生物物質産生・分泌促進剤 |
WO2014004647A1 (en) * | 2012-06-26 | 2014-01-03 | Entia Biosciences, Inc. | A nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2 |
JP6121597B1 (ja) | 2016-06-09 | 2017-04-26 | 株式会社スリービー | 免疫応答活性化サイトカイン産生促進剤およびTh17細胞分化促進剤 |
JP2017218431A (ja) * | 2016-06-09 | 2017-12-14 | 株式会社スリービー | 免疫応答活性化サイトカイン産生促進剤およびTh17細胞分化促進剤 |
Also Published As
Publication number | Publication date |
---|---|
EP4331582A1 (en) | 2024-03-06 |
US20240122899A1 (en) | 2024-04-18 |
AU2022265114A1 (en) | 2023-10-12 |
JPWO2022230494A1 (ja) | 2022-11-03 |
CN117255683A (zh) | 2023-12-19 |
TW202308615A (zh) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090053197A1 (en) | Transfer Factor Compositions and Methods | |
KR20230152614A (ko) | 인지 기능 속도 개선용 조성물 | |
US20200397861A1 (en) | Process of preparation of glycan compositions & uses thereof | |
US20110129548A1 (en) | Immunopotentiating Compositions Comprising Beta-1, 3/1, 6-D-Glucan and Uses Thereof | |
WO2022230494A1 (ja) | 免疫細胞の代謝促進用組成物 | |
WO2022230487A1 (ja) | 赤血球及び/又はヘモグロビン増加用組成物 | |
WO2022230493A1 (ja) | 白血球及び/又は好塩基球増加用組成物 | |
WO2024038821A1 (ja) | フレイル予防又は改善用組成物、及び、加齢に伴う身体活動能力低下を抑制又は改善するための組成物 | |
WO2022230491A1 (ja) | 腎機能の低下抑制又は改善用組成物 | |
Ma et al. | Influence of Ligustrum lucidum and Schisandra chinensis fruits on antioxidative metabolism and immunological parameters of layer chicks | |
WO2022230486A1 (ja) | 脂肪分解促進用組成物 | |
ES2341163B1 (es) | Composiciones inmunoestimulantes. | |
WO2023063230A1 (ja) | セサミン類及びエルゴチオネイン又はその塩を含有する組成物 | |
WO2023090260A1 (ja) | ヒスタミン-n-メチルトランスフェラーゼ阻害用組成物 | |
KR20190063536A (ko) | 1-팔미토일-2-리놀레오일-3-아세틸글리세롤을 포함하는 급성 방사선 증후군의 예방 또는 치료용 조성물 | |
AU2022417968A1 (en) | Oral composition and method for suppressing bitterness derived from ergothioneine | |
WO2024029393A1 (ja) | 経口組成物、並びに、エルゴチオネイン又はその塩に由来する苦味及び乳由来セラミド含有素材に由来する臭みを抑制する方法 | |
US20040213856A1 (en) | Compositions and methods for treatment of multiple myeloma | |
RU2370262C1 (ru) | Препарат для лечения и профилактики болезней, связанных с дефицитом селена для сельскохозяйственных животных | |
TW202342005A (zh) | 經口組成物,及,抑制源自麥角硫因或其鹽之苦味及源自二十碳五烯酸類之臭味之方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22795412 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 804168 Country of ref document: NZ Ref document number: 2022265114 Country of ref document: AU Ref document number: AU2022265114 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023517172 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2022265114 Country of ref document: AU Date of ref document: 20220325 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18286634 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280030903.7 Country of ref document: CN Ref document number: 2301006979 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022795412 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022795412 Country of ref document: EP Effective date: 20231127 |